FDA pulls authorization for COVID antibody treatment over lack of effectiveness ...Middle East

The Hill - News
FDA pulls authorization for COVID antibody treatment over lack of effectiveness
Evusheld, the preventative monoclonal antibody treatment for COVID-19, has lost its emergency use authorization in the U.S. as it is most likely not effective against the strains of the coronavirus currently circulating. The announcement from the Food and Drug Administration (FDA) comes weeks after the agency issued a notice saying it did not expect Evusheld to be effective against the XBB.1.5 omicron subvariant, responsible for 61 percent of cases in the country, according to the most recent federal data. "Today’s action to limit the use of Evusheld prevents exposing patients to possible side effects of Evusheld such as allergic reactions, which can be potentially serious, at a time

Hence then, the article about fda pulls authorization for covid antibody treatment over lack of effectiveness was published today ( ) and is available on The Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA pulls authorization for COVID antibody treatment over lack of effectiveness )

Apple Storegoogle play

Last updated :

Also on site :